The effect of Xuefu Zhuyu decoction on clopidogrel resistance and its association with the P2Y12 Gene polymorphisms and promoter DNA methylation

被引:3
|
作者
Yu, Qinglin [1 ]
Su, Jia [2 ]
Zhu, Keqi [1 ]
Yang, Shujun [3 ]
Zhu, Hao [4 ]
Yu, Jingbo [2 ]
机构
[1] Ningbo 1 Hosp, Dept Tradit Chinese Internal Med, Ningbo, Zhejiang, Peoples R China
[2] Ningbo 1 Hosp, Dept Gerontol, Ningbo, Zhejiang, Peoples R China
[3] Ningbo 1 Hosp, Dept Hematol, Ningbo, Zhejiang, Peoples R China
[4] Ningbo 1 Hosp, Dept Anaesthesia, Ningbo, Zhejiang, Peoples R China
关键词
Xuefu Zhuyu decoction; clopidogrel resistance; P2Y12; polymorphisms; promoter DNA methylation; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT PLATELET REACTIVITY; ANTIPLATELET THERAPY; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; BLOOD-CIRCULATION; PRASUGREL; DETERMINANTS; METAANALYSIS; EXPRESSION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Some patients experience lesser degrees of platelet inhibition, which is known as clopidogrel resistance (CR). The goal of our study was to investigate the effects of Xuefu Zhuyu decoction on CR in coronary artery disease patients and whether P2Y12 polymorphisms and its methylation were related to drug response or not. 49 patients diagnosed with CR were randomly divided into control and treatment groups. Platelet functions were measured using Verify-Now P2Y12 assay. By restriction fragment length polymorphism-polymerase chain reaction, the single-nucleotide polymorphisms of rs2046934 and rs6785930 were genotyped. Using bisulphite pyrosequencing assay, we investigated the association of the P2Y12 gene DNA methylation levels and the effects of Xuefu Zhuyu decoction on CR. The results showed that the decoction improved CR (P= 0.005), and the patients with the TT genotype in rs2046934 received substantial benefits from Xuefu Zhuyu Decoction, in both P2Y12 reaction units (PRU) and inhibition percentage (P-PRU= 0.016; P-inhibition percentage = 0.028). And patients with lower methylation levels of CpG1 were more likely to be TT carriers in rs2046934 (CpG1(TT) Vs. CpG1(TC+CC)(%): 39.47 +/- 6.20 vs.45.70 +/- 8.47, P=0.044). In conclusion, our study indicated that Xuefu Zhuyu decoction might be useful for overcoming CR and the polymorphism of rs2046934 might influence the drug effect.
引用
收藏
页码:2565 / 2572
页数:8
相关论文
共 50 条
  • [31] The antiplatelet effect of ASP1645, a novel P2Y12 receptor antagonist, compared with clopidogrel
    Uemura, T.
    Kawasaki, T.
    Sakata, C.
    Shigenaga, T.
    Moritani, Y.
    Takasaki, J.
    Koga, Y.
    Ito, H.
    Mutoh, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 946 - 946
  • [32] Clopidogrel Resistance and the Effect of Combination Cilostazol in Patients with Ischemic Stroke or Carotid Artery Stenting Using the VerifyNow P2Y12 Assay
    Maruyama, Hajime
    Takeda, Hidetaka
    Dembo, Tomohisa
    Nagoya, Harumitsu
    Kato, Yuji
    Fukuoka, Takuya
    Deguchi, Ichiro
    Horiuchi, Yohsuke
    Tanahashi, Norio
    INTERNAL MEDICINE, 2011, 50 (07) : 695 - 698
  • [33] Dual P2Y12 and CYP2C19 gene polymorphism as a better marker of clopidogrel resistence
    Malek, L. A.
    Kisiel, B.
    Spiewak, M.
    Filipiak, K. J.
    Grabowski, M.
    Kostrzewa, G.
    Ploski, R.
    Opolski, G.
    EUROPEAN HEART JOURNAL, 2007, 28 : 126 - 127
  • [34] Relation between the P2Y12 receptor gene variant and response to clopidogrel in patients with acute coronary syndromes
    Malek, L. A.
    Kisiel, B.
    Spiewak, M.
    Filipiak, K. J.
    Glowczynska, R.
    Grabowski, M.
    Ploski, R.
    Opolski, G.
    EUROPEAN HEART JOURNAL, 2006, 27 : 758 - 758
  • [35] Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease
    Ziegler, S
    Schillinger, M
    Funk, M
    Felber, K
    Exner, M
    Mlekusch, W
    Sabeti, S
    Amighi, J
    Minar, E
    Brunner, M
    Müller, M
    Mannhalter, C
    STROKE, 2005, 36 (07) : 1394 - 1399
  • [36] Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease
    Ziegler, S
    Schillinger, M
    Funk, M
    Exner, M
    Minar, E
    Brunner, M
    Mannhalter, C
    Müller, M
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1085 - 1085
  • [37] Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel
    Malek, Lukasz A.
    Kisiel, Bartlomiej
    Spiewak, Mateusz
    Grabowski, Marcin
    Filipiak, Krzysztof J.
    Kostrzewa, Grazyna
    Huczek, Zenon
    Ploski, Rafal
    Opolski, Grzegorz
    CIRCULATION JOURNAL, 2008, 72 (07) : 1165 - 1169
  • [38] Correlation analysis between gene single nucleotide polymorphisms of P2Y12 and coronary heart disease
    Zhang Xinxia
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (16) : C117 - C117
  • [39] A Comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 Assay for the Assessment of Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention
    Jang, Jiyoung
    Lim, Jihyang
    Chang, Kiyuk
    Kim, Yonggoo
    Kim, Myungshin
    Park, Hae Il
    Kim, Jayoung
    Shin, Soyoung
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2012, 26 (04) : 262 - 266
  • [40] EFFECTS OF CYP2C19 AND P2Y12 GENE POLYMORPHISMS ON CLINICAL RESULTS OF PATIENTS USING CLOPIDOGREL AFTER ACUTE ISCHEMIC CEREBROVASCULAR DISEASE
    Sen, H. M.
    Silan, F.
    Silan, C.
    Degirmenci, Y.
    Kamaran, Ozisik H., I
    BALKAN JOURNAL OF MEDICAL GENETICS, 2014, 17 (02) : 37 - 41